Autoimmune hepatitis overview: Difference between revisions

Jump to navigation Jump to search
Line 20: Line 20:


==Pathophysiology==
==Pathophysiology==
[[Autoimmune hepatitis]] is a chronic disease characterized by [[inflammation]] of the [[liver]] which results from the combination of [[genetic]] predisposition and [[environmental]] triggers. The genetic predisposition is related to the defect in [[HLA]] haplotypes B8, B14, DR3, DR4, and Dw3, [[complement]] system, and [[T]]-cell level. The environmental factors involved are viruses like [[Rubella]], [[Epstein Barr virus|Epstein-Barr]], [[Hepatitis]] A, B, and C have molecular mimicry of viral sequences to host proteins and drugs like [[Oxyphenisatine|oxyphenisatin]], [[methyldopa]], [[nitrofurantoin]], [[diclofenac]], [[interferon]], [[minocycline]], and [[atorvastatin]] causes [[autoimmune hepatitis]].


==Causes==
==Causes==

Revision as of 22:58, 1 January 2018

https://https://www.youtube.com/watch?v=aC0_yOlfY4U%7C350}}

Autoimmune hepatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating autoimmune hepatitis differential diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Diagnostic of choice

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hepatitis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hepatitis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hepatitis overview

CDC on Autoimmune hepatitis overview

Autoimmune hepatitis overview in the news

Blogs on Autoimmune hepatitis overview

Directions to Hospitals Treating Autoimmune hepatitis

Risk calculators and risk factors for Autoimmune hepatitis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Autoimmune hepatitis (AH) was first described in the 1950s and has had a variety of names including chronic active hepatitis, lupoid hepatitis, plasma cell hepatitis and autoimmune chronic active hepatitis. It is characterized by circulating autoantibodies and a high serum globulin level. It is important to distinguish AH from other forms of liver disease, as a large percentage of patients respond to therapy and therapy has been shown to delay transplantation, improve the quality of life as well as prolong survival. Lupoid hepatitis (also called Autoimmune hepatitis) is an auto-immune disease which causes liver cirrhosis. It may be associated with systemic lupus erythematosus (SLE) or other connective tissue disorders. 60% of patients have chronic hepatitis that may mimic viral hepatitis, but without serologic evidence of a viral infection. The disease usually affects women and is strongly associated with anti-smooth muscle auto-antibodies. Autoimmune hepatitis is a condition in which the patient's own immune systems attacks the liver causing inflammation and liver cell death. The condition is chronic and progressive. Although the disease is chronic, many patients with autoimmune hepatitis present acutely ill with jaundice, fever and sometimes symptoms of severe hepatic dysfunction, a picture that resembles acute hepatitis. Autoimmune hepatitis usually occurs in women (70 %) between the ages of 15 and 40. Although the term "lupoid" hepatitis was originally used to describe this disease, patients with systemic lupus erythematosus do not have an increased incidence of autoimmune hepatitis and the two diseases are distinct entities. Patients usually present with evidence of moderate to severe hepatitis with elevated serum ALT and AST activities in the setting of normal to marginally elevated alkaline phosphatase and gamma-glutamyltranspeptidase activities. The patient will sometimes present with jaundice, fever, and right upper quadrant pain and occasionally systemic symptoms such as arthralgias, myalgias, polyserositis and thrombocytopenia. Some patients will present with mild liver dysfunction and have only laboratory abnormalities as their initial presentation. Others will present with severe hepatic dysfunction.[1]

Historical Perspective

Autoimmune hepatitis was first to describe under the name of lupoid hepatitis in young females in early 1950. In 1950, Waldenstrom described a form of chronic hepatitis in young women. The term autoimmune hepatitis was first used by the international panel. Gene mutations implicated in the pathogenesis of autoimmune hepatitis is C4 gene.

Classification

According to European Association for the Study of the Liver, There are three types of Autoimmune hepatitis based on the types of antibodies present- AIH type 1, AIH type 2, AIH type 3. Overlap syndrome is a type of syndrome found in a patient who presents with the features of AIH , PBC-AIH or PSC-AIH.

Pathophysiology

Autoimmune hepatitis is a chronic disease characterized by inflammation of the liver which results from the combination of genetic predisposition and environmental triggers. The genetic predisposition is related to the defect in HLA haplotypes B8, B14, DR3, DR4, and Dw3, complement system, and T-cell level. The environmental factors involved are viruses like Rubella, Epstein-Barr, Hepatitis A, B, and C have molecular mimicry of viral sequences to host proteins and drugs like oxyphenisatin, methyldopa, nitrofurantoin, diclofenac, interferon, minocycline, and atorvastatin causes autoimmune hepatitis.

Causes

Differentiating Autoimmune Hepatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnosis Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

References

  1. Krawitt, E. L. 1996. Autoimmune hepatitis. New England Journal of Medicine. 334:897-903.